With ongoing research into integrating targeted therapies into first-line treatments, including HER2 and BRAF inhibitors, and the emerging utility of circulating tumor DNA for real-time molecular profiling, there has been a palpable shift towards more tailored therapeutic strategies. The gene discussed is ERBB2; the disease is neoplasm.